Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CRVS Corvus Pharmaceuticals	$5.19 -0.4%	$4.31	$2.54 ▼ $10.00	$386.71M	0.42	805,474 shs	351,255 shs
IVA Inventiva	$4.58 +2.9%	$3.38	$1.53 ▼ $4.64	$438.13M	0.73	17,825 shs	29,393 shs
TNXP Tonix Pharmaceuticals	$36.05 -1.3%	$41.37	$6.76 ▼ $130.00	$316.16M	1.7	1.40 million shs	1.54 million shs
VXRT Vaxart	$0.36 -3.4%	$0.44	$0.26 ▼ $1.07	$81.29M	1.12	3.02 million shs	1.05 million shs

10 Best Stocks to Own: Fall 2025

Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CRVS Corvus Pharmaceuticals	-2.07%	+15.78%	+22.30%	+43.53%	+23.17%
IVA Inventiva	-2.83%	+21.53%	+35.73%	+43.41%	+90.60%
TNXP Tonix Pharmaceuticals	-8.83%	-38.87%	-22.13%	+28.94%	-17.91%
VXRT Vaxart	+0.80%	-5.04%	-16.48%	-19.64%	-60.82%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CRVS Corvus Pharmaceuticals	2.8889 of 5 stars	3.5	2.0	2.2	3.3	0.6
IVA Inventiva	3.3333 of 5 stars	3.4	5.0	2.9	1.7	0.6
TNXP Tonix Pharmaceuticals	2.6484 of 5 stars	3.5	2.0	3.0	1.7	0.6
VXRT Vaxart	3.0793 of 5 stars	3.5	5.0	1.7	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CRVS Corvus Pharmaceuticals	3.00	Buy	$15.00	189.02% Upside
IVA Inventiva	2.80	Moderate Buy	$10.40	127.07% Upside
TNXP Tonix Pharmaceuticals	3.00	Buy	$70.00	94.17% Upside
VXRT Vaxart	3.00	Buy	$2.00	463.22% Upside

Current Analyst Ratings Breakdown

Latest VXRT, IVA, TNXP, and CRVS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target	Details
6/3/2025	TNXP Tonix Pharmaceuticals	Alliance Global Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
5/20/2025	CRVS Corvus Pharmaceuticals	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Outperform ➝ Outperform	$12.00 ➝ $11.00

(Data available from 8/20/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CRVS Corvus Pharmaceuticals	N/A	N/A	N/A	N/A	$1.08 per share	N/A
IVA Inventiva	$9.20M	47.63	N/A	N/A	($1.21) per share	-3.79
TNXP Tonix Pharmaceuticals	$10.09M	31.33	N/A	N/A	$19.17 per share	1.88
VXRT Vaxart	$47.40M	1.72	N/A	N/A	$0.26 per share	1.37

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CRVS Corvus Pharmaceuticals	-$62.29M	-$1.01	N/A	N/A	N/A	N/A	-28.61%	-18.05%	N/A
IVA Inventiva	-$199.34M	N/A	0.00	N/A	N/A	N/A	N/A	N/A	9/25/2025 (Estimated)
TNXP Tonix Pharmaceuticals	-$130.04M	-$39.47	N/A	N/A	N/A	-828.22%	-57.93%	-51.04%	N/A
VXRT Vaxart	-$66.95M	-$0.25	N/A	N/A	N/A	-122.63%	-91.89%	-38.40%	N/A

Latest VXRT, IVA, TNXP, and CRVS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
8/11/2025	Q1 2025	TNXP Tonix Pharmaceuticals	-$3.10	-$3.86	-$0.76	-$3.86	$2.60 million	$2.00 million
8/7/2025	Q2 2025	CRVS Corvus Pharmaceuticals	-$0.13	-$0.10	+$0.03	-$0.10	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CRVS Corvus Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
IVA Inventiva	N/A	N/A	N/A	N/A	N/A
TNXP Tonix Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
VXRT Vaxart	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CRVS Corvus Pharmaceuticals	N/A	8.91	8.91
IVA Inventiva	N/A	0.92	0.92
TNXP Tonix Pharmaceuticals	N/A	7.53	7.22
VXRT Vaxart	N/A	0.64	0.64

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CRVS Corvus Pharmaceuticals	46.64%
IVA Inventiva	19.06%
TNXP Tonix Pharmaceuticals	82.26%
VXRT Vaxart	18.05%

Insider Ownership

Company	Insider Ownership
CRVS Corvus Pharmaceuticals	31.30%
IVA Inventiva	32.00%
TNXP Tonix Pharmaceuticals	0.03%
VXRT Vaxart	2.80%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CRVS Corvus Pharmaceuticals	30	74.51 million	51.19 million	Optionable
IVA Inventiva	100	95.66 million	65.05 million	Not Optionable
TNXP Tonix Pharmaceuticals	50	8.77 million	8.76 million	Not Optionable
VXRT Vaxart	120	228.92 million	222.37 million	Optionable

VXRT, IVA, TNXP, and CRVS Headlines

Recent News About These Companies

Vaxart (NASDAQ:VXRT) Shares Cross Below 200-Day Moving Average - Should You Sell?

August 16, 2025 | marketbeat.com

Vaxart, Inc. (VXRT) Q2 2025 Earnings Call Transcript

August 13, 2025 | seekingalpha.com

VAXART, INC. (VXRT) Reports Q2 Loss, Beats Revenue Estimates

August 13, 2025 | zacks.com

US orders Vaxart to stop COVID-19 trial amid mRNA wind down

August 13, 2025 | reuters.com

Vaxart (NASDAQ:VXRT) Stock Price Passes Below 200-Day Moving Average - Here's Why

August 7, 2025 | marketbeat.com

Vaxart (VXRT) Expected to Announce Earnings on Thursday

August 7, 2025 | marketbeat.com

Vaxart, Inc. Stock (VXRT) Opinions on Reverse Stock Split Proposal

July 31, 2025 | quiverquant.comQ

Vaxart (NASDAQ:VXRT) Stock Price Crosses Below 200 Day Moving Average - Here's Why

July 29, 2025 | marketbeat.com

Vaxart Submits Proxy Statement for Reverse Stock Split to Support Resumption of Trading on Nasdaq

July 24, 2025 | globenewswire.com

OTC Markets Group Welcomes Vaxart, Inc. to OTCQX

July 8, 2025 | financialpost.comF

Vaxart Announces Preliminary Results of Annual Meeting of Stockholders

June 13, 2025 | globenewswire.com

Vaxart Reports Positive Clinical Data Demonstrating that its Second-Generation Vaccine Technology Produces Much Stronger Antibody Responses than its First-Generation Technology

June 11, 2025 | globenewswire.com

Vaxart, Inc. to Release Topline Data from Norovirus Phase I Trial on June 11, 2025

June 10, 2025 | quiverquant.comQ

Vaxart to Host Conference Call on June 11 at 8:30 AM ET to Discuss Topline Results from Its Phase I Norovirus Trial

June 10, 2025 | globenewswire.com

Vaxart Announces Adjournment of Annual Meeting of Stockholders

June 2, 2025 | globenewswire.com

Vaxart to Participate at the Jefferies Global Healthcare Conference on June 5, 2025

May 29, 2025 | globenewswire.com

Vaxart's Dr. Sean Tucker Calls on Stockholders to Support Reverse Stock Split Proposal by June 1, 2025

May 29, 2025 | quiverquant.comQ

Vaxart's Founder and Chief Scientific Officer Provides Video Update to Stockholders

May 29, 2025 | globenewswire.com

Vaxart Discusses Reverse Stock Split and Capital Raise

May 28, 2025 | tipranks.com

Vaxart Answers Additional Frequently Asked Questions from Retail Investors

May 28, 2025 | globenewswire.com

Vaxart Initiates Dosing in 10,000-Participant Portion of Phase 2b COVID-19 Trial

May 27, 2025 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

VXRT, IVA, TNXP, and CRVS Company Descriptions

Corvus Pharmaceuticals NASDAQ:CRVS

$5.19 -0.02 (-0.38%)

Closing price 04:00 PM Eastern

Extended Trading

$5.23 +0.04 (+0.77%)

As of 05:37 PM Eastern

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis. The company is also developing ciforadenant (CPI-444), an oral small molecule antagonist of the A2A receptor that is in Phase 2 clinical trial for the treatment of metastatic renal cell cancer; and mupadolimab (CPI-006), a humanized monoclonal antibody, which is in Phase 1b clinical trial for the treatment of non-small cell lung cancer and head and neck cancer. In addition, it is developing CPI-182, an antibody designed to block inflammation and myeloid suppression that is in investigational new drug application-enabling studies, as well as CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a license afreemnt with Monash University to research, develop, and commercialize certain antibodies directed to CXCR2 for the treatment of human diseases; and Vernalis (R&D) Limited to develop, manufacture, and commercialize products containing certain adenosine receptor antagonists, including ciforadenant, as well as strategic collaboration with Angel Pharmaceuticals Co. Ltd. for the development and commercialization of mupadolimab. Corvus Pharmaceuticals, Inc. was incorporated in 2014 and is based in Burlingame, California.

Inventiva NASDAQ:IVA

$4.34 -0.11 (-2.45%)

As of 04:00 PM Eastern

Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases. Its lead product candidate is Lanifibranor, which is in Phase III clinical trial to treat NASH. The company also develops Odiparcil for the treatment of patients with mucopolysaccharidoses type VI. In addition, it has a pipeline of earlier stage programs in oncology and other diseases. The company was founded in 2011 and is headquartered in Daix, France.

Tonix Pharmaceuticals NASDAQ:TNXP

$36.05 -0.48 (-1.31%)

Closing price 04:00 PM Eastern

Extended Trading

$36.40 +0.35 (+0.97%)

As of 05:42 PM Eastern

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults. Its portfolio focuses on central nervous system disorders, as well as rare disease, immunology, and infectious disease product candidates. The company's priority is to submit a New Drug Application (NDA) to the FDA for TNX-102 SL (cyclobenzaprine HCl sublingual tablet), which has completed two positive Phase 3 studies for the management of fibromyalgia. TNX-102 SL is also being developed to treat fibromyalgia-type Long COVID, a chronic post-acute COVID-19 condition. Its TNX-1300 (cocaine esterase) is a biologic designed to treat cocaine intoxication and has been granted breakthrough therapy designation by the FDA. The company's rare disease development portfolio comprises TNX-2900, an intranasal potentiated oxytocin for the treatment of Prader-Willi syndrome (PWS). Its immunology portfolio includes TNX-1500, which is a biologic to address organ transplant rejection and autoimmune diseases. The company's infectious disease pipeline includes TNX-801, a vaccine in development to prevent smallpox and mpox. TNX-801 also serves as the live virus vaccine platform or recombinant pox vaccine platform for other infectious diseases, including TNX-1800 and TNX-1850, in development as a vaccine to protect against COVID-19. Its infectious disease development portfolio also comprises TNX-3900, and TNX-4200 are orally available CD45 antagonists in preclinical development. Tonix Pharmaceuticals Holding Corp. has collaboration agreement with Bilthoven Biologicals to advance TNX-801 mpox vaccine candidate; and with X-Chem, Inc. to develop broad-spectrum antivirals. The company was founded in 2007 and is headquartered in Chatham, New Jersey.

Vaxart NASDAQ:VXRT

$0.36 -0.01 (-3.37%)

As of 03:59 PM Eastern

Vaxart, Inc., a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII.4 norovirus strains; coronavirus vaccine, which is in Phase 2 clinical trial, for the treatment of SARS-CoV-2 infection; seasonal influenza vaccine, which is in Phase 2 clinical trial, to treat H1 influenza infection; and human papillomavirus therapeutic vaccine, which is in preclinical stage, that targets HPV-16 and HPV-18 for cervical cancers and precancerous cervical lesions. It has a license agreement with Altesa Biosciences, Inc. to develop and commercialize Vapendavir, a capsid-binding broad-spectrum antiviral. Vaxart, Inc. is headquartered in South San Francisco, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time